Exchange: NASDAQ·Updated 04:50 AM EDT

BEAM News

News
all
press releases
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
Stocktwits
More News
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Stocktwits
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
Zacks
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beam Therapeutics Inc. (Beam or the Company) (NASDAQ: BEAM) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses...
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMPR NewswireNEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026 /PRNewswire...
PR Newswire
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Zacks
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accelerated FDA approval with a 60 mg dose.read more...
Benzinga
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Zacks
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.
Zacks
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.